key: cord-0731079-1boooi9w
authors: Mattone, E.; Sofia, M.; Schembari, E.; Palumbo, V.; Bonaccorso, R.; Randazzo, V.; La Greca, G.; Iacobello, C.; Russello, D.; Latteri, S.
title: Acute acalculous cholecystitis on a COVID-19 patient: A case report
date: 2020-08-31
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2020.08.027
sha: af62474aeddecd8ebd0a58933807fe4d88070ef3
doc_id: 731079
cord_uid: 1boooi9w

INTRODUCTION: We report an extremely rare case of acute acalculous cholecystitis on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient. PRESENTATION OF CASE: A COVID-19 patient was diagnosed with acute acalculous cholecystitis and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient's clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous, the severe inflammation made surgery difficult to perform. DISCUSSION: Acalculous cholecystitis was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous histopathology pattern and the gallbladder wall ischemia was probably caused by vascular insufficiency secondary to severe acute respiratory distress syndrome of COVID-19 pneumonia. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia, nausea, vomiting, and diarrhoea. CONCLUSIONS: Although the lack of evidence and guidelines about the management of patient with acute cholecystitis during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis on COVID-19 patients.

SARS-CoV-2 is a novel coronavirus that has not been previously identified in humans and it's responsible of coronavirus disease-19 (COVID-19) which has spread to several countries around the world and has become an unprecedented pandemic 1 . Infected patients have been reported with common clinical symptoms such as fever, cough, myalgia, dyspnoea and normal or decreased leukocyte counts 2 . COVID-19 patients have been shown to undergo severe acute respiratory distress syndrome, caused by cytokine storm and this is the foremost reason for morbidity and mortality due to multiple organ failure 3 . Although many patients reported gastrointestinal symptoms such as anorexia, nausea, vomiting and diarrhoea, there was no evidence about the involvement of gallbladder and biliary tract in literature to date. We report an extremely rare case of acute acalculous cholecystitis on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient. The paper has been reported in line with the SCARE 2018 criteria 4 .

A 66-year-old man, ex-smokers since 2006 with no drug and inheritable genetic diseases history, was admitted to our hospital with fever (38,2°C), non-productive cough, and dyspnoea started by 10-days, after a holiday cruise. The clinical parameters were: 95/min. heart rate, 135/90 mmHg blood arterial pressure and 87%O2 saturation. Respiratory rate was 35/min. breaths, vocal fremitus was diminished bilaterally, especially at the base of the lung, with dullness on percussion and rhonchi, wheezes and rubs at auscultation. The physical examination of the abdomen was negative. The laboratory findings revealed normal white blood cell (WBC) 5.80 K/aeL and high C-reactive protein (CRP) level, 8.20 mg/dL. Chest X-ray showed interstitial lung disease and nasopharyngeal swab-PCR was positive for SARS-CoV-2 infection. The patient was diagnosed with COVID-19 pneumonia and he has been intubated because of respiratory distress. COVID-19 infection was treated in intensive care unit by hydroxychloroquine 200 mg., azithromycin 500 mg., tocilizumab 60 mg., methylprednisolone 70 mg. and enoxaparin 4.000 U.I. This therapeutic protocol led good clinical result, as shown by chest X-rays that reported a decrease of interstitial lung disease after 34-days of hospital stay. At 49th day of hospitalization patient complained right upper quadrant abdominal pain together with nausea, vomiting and mild corporeal temperature (38°C). The physical examination revealed a tender abdomen with normal peristaltic bowel movements, no jaundice and a positive Murphy's sign. Blood tests showed mild leucocytosis, 11.90 K/aeL, with a shift to the left of neutrophils, 80.80%, and high CRP level, 6.60 mg/dL. The abdominal computed tomography (CT) revealed a severe gallbladder distension, pericholecystic fluid, marked gallbladder wall thickening, no gallstones were identified and the extrahepatic bile ducts were normal. The patient was diagnosed with acute acalculous cholecystitis and a multidisciplinary team including general surgery unit, interventional radiology unit, intensive care unit and infectious disease unit, had discussed the therapeutic choices for patient.

A percutaneous transhepatic biliary drainage (PTBD) under ultrasound control of gallbladder, was performed as the first. A sample of bile was tested for SARS-CoV-2 RNA and it was negative. After 3-days there was no clinical improvement with persistent high WBC count, 13.50 K/aeL. The multidisciplinary team met and a laparoscopic surgical procedure was planned. Laparoscopic cholecystectomy was made by the chief of general surgery helped by a consultant surgeon and it was performed through four ports. The gallbladder was gangrenous and a severe inflammation make the Calot's elements difficult to identify. However, the cystic duct and the cystic artery were eventually identified and dissected. Therefore, cholecystectomy was finished. The operative time was 105 minutes. On the 3th post-operative day nasopharyngeal swab-PCR became negative for SARS-CoV-2 RNA and further nasopharyngeal swab-PCR performed after 48 hours and after 96 hours were negative too. The postoperative course was uneventful and it was welltolerated by the patient, so he was discharged on the 9th postoperative day in satisfactory condition.

Acalculous cholecystitis is an uncommon disease caused by hypomotility of the gallbladder which is responsible of increased intraluminal pressures evolving in inflammation, ischemia and necrosis 5 . It accounts for only 10% of acute cholecystitis but it has higher morbidity and mortality than calculous cholecystitis [6] [7] . Acalculous cholecystitis is also strictly related with other pathological condition such as trauma, cardiopulmonary resuscitation, mechanical ventilation, sepsis, burn, prolonged total parenteral nutrition and major surgery 5 . In addition, Croteau et al. reported seven cases of acute acalculous cholecystitis occurred in patients with relapsing -remitting multiple sclerosis during or shortly after alemtuzumab treatment, suggesting an acute cytokine release syndrome as a pathogenic mechanism 8 . Gangrenous cholecystitis is caused by ischemia arising from vascular insufficiency and it evolves into necrosis and perforation of the gallbladder wall with bile leakage 9 . Surgical societies released their recommendations to manage surgical disease during the COVID-19 pandemic 10 . The recommendations on emergency surgery have fuelled a debate among surgeons on an international level 10 . Reports from China showed that asymptomatic COVID-19-positive patients underwent surgery presented poor clinical outcomes, with an increasing of mortality and pulmonary complication rate 11 . In the present case acalculous cholecystitis was related with mechanical ventilation and prolonged total parenteral nutrition, instead the gangrenous histopathology pattern was probably caused by severe acute respiratory distress syndrome of COVID-19 pneumonia which determined vascular insufficiency, responsible of gallbladder wall ischemia. Although laparoscopic cholecystectomy is considered the gold standard for the treatment of most gallbladder disease 12 , Tokyo Guidelines advice to delay surgical operation and to perform the percutaneous gallbladder drainage for surgically high-risk patients with acute cholecystitis and comorbidities 13 . Multidisciplinary team decided to perform surgery after cholecystostomy due to worsening clinical condition of the patient, presenting fever and right upper quadrant abdominal pain and patient agreed with doctors because of his poor clinical conditions. Laparoscopic cholecystectomy was preferred to open cholecystectomy because of the lack of evidence about an increased risk of SARS-CoV-2 infection during laparoscopy 10 . Finally, SARS-CoV-2 RNA was detected from a variety respiratory sources such as throat, nasal nasopharyngeal, sputum and bronchoalveolar lavage fluid, but it was also detected in faeces 14 , placental and foetal membrane 15 . In our acknowledgement this is the first case of attempt at trying to demonstrate the presence of viral RNA in the bile but the result was negative and this highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects small intestinal enterocytes 16 which is responsible of gastrointestinal symptoms such as anorexia, nausea, vomiting, and diarrhoea 17 .

The lack of evidence and guidelines about the management of patient with acute cholecystitis during COVID-19 pandemic lead surgeons from the better decision for patient following the same guidelines used for the assessment and the treatment of COVID-19 negative patient. Therefore, laparoscopic cholecystectomy, preceded by percutaneous transhepatic gallbladder drainage (PTBD) in high-risk patient for surgical treatment, remain the best choice and the gold standard for the treatment of acute cholecystitis on COVID-19 patient.

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Not commissioned, externally peer reviewed. Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

The patient signed informed consent and written permission to use data for scientific purposes.

Series: Medical Virology: From Pathogenesis to Disease Control

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias

For the SCARE Group. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines

Recent advances in management of acalculous cholecystitis

Acute acalculous cholecystitis

Laparo-endoscopic Rendez-Vous Versus Sequential "Delayed" Approach in Patients With CholedocholithiasisClinical Trial Minerva Chir

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab

Clinical presentation, imaging, and management of acute cholecystitis. Techniques in Vascular and Interventional Radiology

Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Dystopic retrohepatic gallbladder and cholecysto-choledocho lithiasis: the rendez-vous and indocyanine green fluorescence.Clin Case Rep

Management Strategies for Gallbladder Drainage in Patients with Acute Cholecystitis (With Videos)

Laboratory diagnosis of emerging human coronavirus infections -the state of the art

Detection of severe acute respiratory syndrome coronavirus 2 in placental and fetal membrane samples. 5Am

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

Gastrointestinal and Liver Manifestations of COVID-19

Author contribution Please specify the contribution of each author to the paper, e.g. study concept or design, data collection

Mattone Edoardo: writing the paper Sofia Maria: data analysis Schembari Elena: data collection Palumbo Valentina: data collection Bonaccorso Rosario: data interpretation Randazzo Valentina: data analysis La Greca Gaetano: data interpretation Iacobello Carmelo: data interpretation Russello Domenico: study concept Latteri Saverio: study concept and design

All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria. The article is original, has not already been published in a journal, and is not currently under consideration by another journal. All authors agree to the terms of the BioMed Central Copyright and License Agreement and Open Data policy.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.This research did not receive any grant from funding agencies in the References public, commercial, or not-for-profit sectors.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.Not applicable.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".